四環醫藥(00460.HK)與旺實生物就新冠治療藥物生產供應達成合作協議
四環醫藥(00460.HK)公布,旗下子公司吉林四環與旺實生物就口服核(甘)類抗新冠1類創新藥氫溴酸氘瑞米德韋片VV116的生產供應達成合作協議。雙方將密切配合推進VV116在技術轉移、委託生產相關工作。
VV116為君實生物(01877.HK)下屬控股子公司旺實生物申報的1類創新藥氫溴酸氘瑞米德韋片,並於上月經國家藥監局應急審評審批,附條件批准上市,該藥被批准用於治療輕中度新冠的成年患者。
根據雙方協議約定及相關藥品管理法規,吉林四環將作為受託生產方配合旺實生物開展產品的工藝優化、質量方法轉移、中試放大、工藝驗證等技術轉移落產及委託生產註冊審批工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.